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Protein kinases are therapeutic targets for human
cancer. However, ‘‘gatekeeper’’ mutations in tyro-
sine kinases cause acquired clinical resistance,
limiting long-term treatment benefits. mTOR is a
key cancer driver and drug target. Numerous small-
molecule mTOR kinase inhibitors have been devel-
oped, with some already in human clinical trials.
Given our clinical experience with targeted therapeu-
tics, acquired drug resistance in mTOR is thought
likely, but not yet documented. Herein, we describe
identification of a hot spot (L2185) for drug-resistant
mutations, which is distinct from the gatekeeper site,
and a chemical scaffold refractory to drug-resistant
mutations. We also provide new insights into mTOR
kinase structure and function. The hot spot muta-
tions are potentially useful as surrogate biomarkers
for acquired drug resistance in ongoing clinical trials
and future treatments and for the design of the next
generation of mTOR-targeted drugs. Our study pro-
vides a foundation for further research into mTOR
kinase function and targeting.
INTRODUCTION
mTOR is a highly conserved serine/threonine protein kinase
belonging to the PI3K-related kinase family (Wullschleger et al.,
2006). mTOR forms two distinct kinase complexes: mTORC1
and mTORC2. mTORC1 controls cell growth and metabolism,
in response to diverse cellular signals, including nutrients,
growth factors, and cytokines (Ma and Blenis, 2009). mTORC2
phosphorylates AKT at Ser473 and promotes cell survival
(Sarbassov et al., 2005). Recent advances in cancer genomic
sequencing have revealed cancer mutations frequently target
mTOR pathway, resulting in hyperactivation of mTOR signaling
that drives uncontrolled cancer growth,metabolism, and survival
(Wood et al., 2007). mTOR is an established molecular target for
cancer therapy, because cancer cells tend to be addicted to
aberrant mTOR signaling and mTOR inhibition is well tolerated446 Cell Reports 11, 446–459, April 21, 2015 ª2015 The Authors(Bjornsti and Houghton, 2004; Guertin and Sabatini, 2007; Tsang
et al., 2007).
Rapamycin is amacrolide natural product and a highly specific
mTOR inhibitor. It forms a complex with FKBP12, which binds to
the FRB domain of mTOR (Chen et al., 1995; Zheng et al., 1995).
Two rapamycin analogs (rapalogs), temsirolimus and everoli-
mus, are FDA-approved drugs for treatment of advanced
renal cell and mammary carcinomas. However, rapamycin only
partially inhibits TOR functions (Zheng et al., 1995), which is
due to selective binding of FKBP12-rapamycin complex to
mTORC1, but not mTORC2 (Loewith et al., 2002). Moreover,
the clinical efficacy of rapalogs is limited with low overall objec-
tive response (Zhang et al., 2011a). Another shortcoming of
rapalogs is that they lead to activation of the IRS1-PI3K-AKT
negative feedback loop, sustaining survival of rapalog-treated
cancer cells (O’Reilly et al., 2006; Sun et al., 2005). For these rea-
sons, it is increasingly recognized that the therapeutic potential
of rapalogs is limited.
The clinical success of ATP-competitive tyrosine kinase inhibi-
tors (TKIs), such as imatinib and gefitinib, illustrates the value of
targeting kinases as an effective anti-cancer strategy (Zhang
et al., 2009). We previously found that mTOR kinase domain is
required for both rapamycin-sensitive and rapamycin-insensitive
aspects of cell growthandsurvival (Zhengetal., 1995), suggesting
that TOR kinase domain is amore-potent site formTOR targeting.
Subsequent studies lent support to this notion and revealed that
the rapamycin-insensitive function is mTORC2 related (Loewith
et al., 2002; Sarbassov et al., 2004). These findings provide a
key rationale for developing ATP-competitive mTOR inhibitors
for cancer therapy (Feldman et al., 2009; Guertin and Sabatini,
2009; Thoreen et al., 2009). In addition to selective mTOR kinase
inhibitors such as PP242, OSI-027, and WYE-354, dual mTOR/
PI3K inhibitors such as BEZ235 and Torin2 have been developed,
which have additional advantage of preventing activation of the
IRS1-PI3K-AKT negative feedback loop. Indeed, mTOR kinase
inhibitors display superior anti-tumor effects compared with
rapalogs in preclinical cancer models and are well tolerated with
excellent toxicological profiles (Zhang et al., 2011b).
Since mTOR kinase inhibitors were described in 2008,
numerous mTOR-kinase-targeting agents have been developed
and entered into human clinical trials for cancer treatment
(Zhang et al., 2011b). The remarkable speed with which human
clinical trials have been initiated and the sheer number of
different compounds being tested in patients underscore their
therapeutic potential. Despite early promising results, major
challenges remain. A comprehensive, mechanistic understand-
ing of these small-molecule inhibitors is lacking. Previous clinical
experience with BCR-ABL and EGFR small-molecule inhibitors
shows that binding-site drug-resistant mutations represent a
major limiting factor for clinical efficacy (Zhang et al., 2009).
In vitro mutagenesis screens have identified resistance muta-
tions in ABL and EGFR kinases that faithfully recapitulate clinical
observations (Azam et al., 2003; Engelman et al., 2006). The pre-
sent study is aimed at developing a simple method and applying
it to understand mTOR kinase function and drug-resistant
mutations.
RESULTS
An S. cerevisiae System for Studying Chemical
Inhibition of mTOR Kinase
TOR is structurally and functionally conserved between humans
and yeast. However, among a large panel of structurally diverse
mTOR kinase inhibitors, only Torin2 and, to a lesser degree,
BEZ235, inhibit yeast growth (Figures 1A and S1), which is
consistent with an earlier observation (Liu et al., 2012). Poor
sensitivity to mTOR inhibitors could be due to low permeability
of yeast cells or insensitivity of yeast TOR kinase to these partic-
ular small molecules. To distinguish the two possibilities, we
engineered a TOR2-mTOR fusion, in which yeast TOR2 kinase
domain is swapped in frame with mTOR kinase domain (Fig-
ure 1B). When expressed under the control of the TOR2 native
promoter in a centromeric plasmid (Figure 1C), TOR2-mTOR
fusion gene suppresses the temperature sensitivity of tor2-dg
strain (Figures 1D and 1E), which carries a genomic TOR2
gene fused with degron, a tag rendering heat-inducible degrada-
tion of tagged proteins (Dohmen and Varshavsky, 2005), indi-
cating that mTOR kinase domain complements the essential
function of TOR2 kinase in yeast.
We next tested sensitivity of tor2-dg cells expressing TOR2-
mTOR to mTOR kinase inhibitors. Similar to wild-type (WT) cells,
tor2-dg cells expressing TOR2 are poorly inhibited by mTOR
kinase inhibitors BEZ235 and OSI-027 (Figure 1E). In contrast,
tor2-dg strain expressing TOR2-mTOR is highly sensitive to
these drugs (Figure 1E). This observation indicates that TOR2
is intrinsically resistant to mTOR kinase inhibitors and that swap-
ping TOR2 kinase domain with mTOR kinase domain renders
yeast sensitivity to mTOR inhibitors.
Even with TOR2-mTOR, tor2-dg strain remains resistant to
majority of mTOR kinase inhibitors (Figure 2A). Yeast is known
to be poorly permeable to small drug molecules (Emter et al.,
2002; Simon and Bedalov, 2004). Deletion of ERG6, PDR1,
and PDR3 has been used to enhance yeast cell permeability
to organic compounds (Gray et al., 1998). However, yeast cells
do not appear to tolerate erg6D in the tor2-dg background
(data not shown). To explore an alternative method, we tested
three different classes of antifungal drugs known to disrupt yeast
cell wall or membrane structures. Amphotericin B, an amphi-
pathic molecule that forms channel-like structures in the fungal
membrane (Ghannoum and Rice, 1999), increases yeast sensi-tivity to most of mTOR kinase inhibitors (Figure 2A). In contrast,
miconazole and caspofungin, antifungal drugs that disrupt
ergosterol-containing yeast membrane and cell wall, respec-
tively, fail to do so (Figures 2B and 2C). Amphotericin B was
used thereafter to facilitate our studies of mTOR kinase inhibitors
in yeast.
Mutational Analysis of ‘‘Gatekeeper’’ Residue in mTOR
Kinase
Non-small-cell lung cancer (NSCLC) patients responding to
initial erlotinib treatment typically relapse within 6 months. In
50% cases, it is due to a single missense mutation, T790M, at
the gatekeeper site of EGFR (Bell et al., 2005; Kobayashi et al.,
2005; Pao et al., 2005). The larger methionine at this position
constrains erlotinib binding, causing drug resistance while
retaining the kinase’s catalytic activity. A similar gatekeeper mu-
tation (T315I) in the ABL kinase domain renders resistance of
chronic myeloid leukemia (CML) to imatinib (Gorre et al., 2001).
These observations suggest the gatekeeper residue contributes
to resistance to ATP-competitive kinase inhibitors.
Based on sequence alignment, the mTOR gatekeeper residue
is predicted to be I2237 (Sturgill and Hall, 2009). It is located
within the hydrophobic pocket of N-lobe of the kinase domain
(Figures 3A, 3B, and S2). In contrast to the conserved threonine
gatekeeper residue in tyrosine kinases, both mTOR and PI3Ka
have a relatively bulky isoleucine at this position (Figure 3A)
(Vogt, 2008; Zunder et al., 2008). To evaluate the significance of
the gatekeeper site, we performed saturation mutagenesis of
I2237 in TOR2-mTOR fusion. Resulting TOR2-mTOR mutants
were assayed for their sensitivity to chemically diverse mTOR
kinase inhibitors. However, noneof themutations exhibit discern-
ible drug resistance (Figure 3C). Strikingly, only the I2237Lmuta-
tion fully preserves mTOR kinase function (Figures 3D and 3E),
suggesting that mTOR’s gatekeeper position does not tolerate
any substitution except the highly conserved leucine, which ex-
plains the lack of drug-resistant gatekeeper mutations. A similar
phenomenon was also observed with another atypical kinase,
PI3Ka (Zunder et al., 2008), suggesting that mTOR and PI3K
are similar with respect to the function of the gatekeeper residue.
Identification of a Non-gatekeeper Hot Spot for Drug-
Resistant Mutations in mTOR Kinase Domain
Yeast is a powerful model organism for genetic screens. We em-
ployed our yeast system and the following strategy to identify
drug-resistant mutations in mTOR kinase domain (Figure 4A).
In this scheme, mTOR kinase mutants are generated through er-
ror-prone PCR amplification and are recombined with a gapped
TOR2 plasmid by ‘‘gap repair’’ to create TOR2-mTOR fusions in
frame through homologous recombination in yeast cells. Gap
repair is an efficient method to generate a library of mutant
clones (Martzen et al., 1999; Uetz et al., 2000). TOR2-mTORmu-
tants are then replica plated onto OSI-027-containing plates to
screen for drug-resistant mutations, which leads to isolation
of drug-resistant clones carrying L2185A and L2185C muta-
tions. Interestingly, these mutations also confer resistance to
AZD8055, INK128, and PF-04691502 (Figure 4B), suggesting
that L2185 is important for binding of structurally diverse
mTOR kinase inhibitors.Cell Reports 11, 446–459, April 21, 2015 ª2015 The Authors 447
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Figure 1. Developing a Yeast System to Assay for mTOR Kinase Inhibition
(A) WT yeast cells were spread onto YPD plates and tested for sensitivity to structurally diverse mTOR kinase inhibitors by disc halo assay. Rapamycin was used
as a positive control.
(B) TheN terminus of TOR2 (1–2,080 aa) was fused in framewithmTOR kinase domain (2,140–2,549 aa). The TOR2-mTOR fusion is expressed under the control of
TOR2 promoter in a centromeric plasmid.
(C) Yeast strain expressing WT TOR2 or TOR2-mTOR fusion was analyzed for expression by immunoblot with an antibody specific for mTOR kinase domain.
PGK1 was used as a loading control, and extracts from MCF7 breast cells were used as a positive control for mTOR.
(D) TOR2-mTOR fusion was expressed in tor2-dg and tested for its ability to complement TOR2 function by growth at permissive and restrictive temperatures.
(E) tor2-dg cells expressing TOR2 or TOR2-mTOR were serially diluted by 10-fold and tested for drug sensitivity on plates containing BEZ235 and OSI-027.To systematically evaluate mutational effect at this position,
we performed saturation mutagenesis of L2185 and systemati-
cally investigated for the potential of each point mutation
to confer drug resistance (Figure 4C). The result shows that
L2185A and L2185C are the most-important mutations, confer-
ring resistance to OSI-027, AZD8055, INK128, PF-04691502,448 Cell Reports 11, 446–459, April 21, 2015 ª2015 The Authorsand PKI-587. In addition, L2185D and L2185N are moderately
resistant to AZD8055, PF-04691502, and PKI-587 and L2185G
to AZD8055, INK128, PF-04691502, and PKI-587. The differen-
tial effect of L2185mutations on different mTOR kinase inhibitors
likely reflects structural diversity of the tested compounds and
distinct requirements at position 2,185. Of note, L2185A and
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Figure 2. Enhancement of Yeast Cell Permeability to Structurally Diverse mTOR Kinase Inhibitors by Amphotericin B
(A) tor2-dg cells expressing TOR2-mTORwere spread on synthetic complete (SC)-leucine plate and tested for drug sensitivity by disc halo assay using filter discs
containing different mTOR kinase inhibitors supplemented with the drug carrier DMSO or amphotericin B (10 mM).
(B) Similar to (A) except the filter discs were supplemented with miconazole (50 mM).
(C) Similar to (A) except the filter discs were supplemented with caspofungin (50 mM).L2185C mutants remain sensitive to BEZ235 and Torin2, two
compounds with closely related chemical structures, suggesting
that a common structural scaffold(s) renders these agents less
susceptible to the binding-site mutations.
L2185AMutation Confers Drug Resistance in Colorectal
and Lung Cancers
To evaluate drug-resistant mutations identified with our yeast
system in human cancer models, we transiently expressedFlag-mTOR(L2185A) in HEK293T cells and found that it confers
resistance to OSI-027 and INK128 (Figure S3A). To test the sig-
nificance of our findings in more physiologically relevant cancer
models, we used the CRISPR/Cas9 genome-editing technology
(Cong et al., 2013; Mali et al., 2013) to integrate L2185A into the
mTOR locus of SW480 colorectal andH460 lung cancer cell lines
(Figure S3B), representing cancer types with high mortality rates
due to lack of efficacious targeted therapy. L2185A mutation
indeed confers resistance to AZD8055, INK128, OSI-027, andCell Reports 11, 446–459, April 21, 2015 ª2015 The Authors 449
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Figure 3. Mutational Analysis of the Gatekeeper Residue in mTOR Kinase
(A) Sequence alignment of the gatekeeper site for PKA, c-KIT, EGFR, ABL, p110-PI3Ka, and mTOR. Arrowhead marks the gatekeeper residue.
(B) Electrostatic model of the ATP-binding pocket of mTOR kinase (PDB ID code 4JSP). The I2237 position is as indicated. Atom is colored as follows:
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PP242 in SW480 colorectal cancer cells (Figures 5A and 5B),
which is accompanied by drug-resistant signaling by both
mTORC1 and mTORC2 (Figure 5C). Independent mutant clones
provide essentially the same phenotype (Figure S3C), indicating
that off-target effect is unlikely. Interestingly, we did not observe
significant differences in drug resistance between heterozygous
and homozygous mutants (Figures S3C and S3D), suggesting
that the mutant allele is dominant. Notably, AKT(S473) phos-
phorylation is moderately more drug resistant than S6K1(T389)
phosphorylation in mTOR(L2185A) versus WT cells (Figure 5C),
suggesting that L2185A mutation differentially affects drug
binding in two different mTOR complexes. Comparable results
were obtained with H460 lung cancer cells with select com-
pounds (Figures S3E and S3F), suggesting that drug resistance
by L2185A is not tumor type specific.
As seen in yeast, the L2185A mutant remains sensitive to
BEZ235 and Torin2 in colorectal and lung cancer cells (Figures
5D and S3G). Curiously, although L2185A confers resistance to
PF-04691502 in the yeast assay (Figure 4B), SW480 cells car-
rying this mutation are still sensitive to PF-04691502 (Figure 5G).
Because PF-04691502 is an mTOR/PI3K dual inhibitor, the
discrepancy between yeast and human cells may be attributed
to inhibition of type I PI3Ks in colorectal cancer cells by PF-
04691502, which is absent from yeast. To determine whether
L2185A renders drug resistance in vivo, we generated xenograft
tumors derived from SW480 cells carrying WT or L2185A
mutant mTOR. When delivered via intraperitoneal injection,
INK128 strongly attenuates growth of WT mTOR tumors but
has little or no effect on mTOR(L2185A)-bearing tumors (Figures
6A–6D). Similarly, L2185A renders xenograft tumors’ drug resis-
tance in mTORC1 and mTORC2 signaling in xenograft tumors,
which is in contrast to the complete blockage of mTOR
signaling in WT mTOR tumors (Figure 6F). Together, these re-
sults demonstrate that L2185A confers drug resistance in vitro
and in vivo.
Mutational Analysis of Conserved Hydrophobic Pocket
‘‘Hydrophobic spines’’ within the active site are increasingly
recognized to the binding of ATP and ATP-competitive inhibitors
of protein kinases (Kornev et al., 2006). The recently published
crystal structure of mTOR kinase domain provides a detailed
3D view of mTOR’s ATP-binding site (Yang et al., 2013). Several
residues, including I2163, L2185, Y2225, I2237, and W2239, are
highly conserved in PI3K and PI3K-related kinases (Figure S2).
They appear to form an N-lobe-like hydrophobic pocket involved
in binding of ATP and ATP-competitive mTOR inhibitors (Fig-
ure 7A). To understand their significance, we systematically
mutated them and determined the effect of the substitutions
with the yeast growth assay (Figure 7B). Most of the mutations
cause loss of mTOR catalytic activity to different degrees, with
only 10%–35% retaining normal mTOR kinase function (Fig-
ure 7C). Interestingly, over 50% hydrophobic substitutions retain(C) tor2-dg cells expressing WT or mutant TOR2-mTORwere serially diluted by 10
OSI-027, or Torin2 or AZD8055, BEZ235, INK128, PF-04691502, or PKI-587 in th
(D) tor2-dg cells expressing WT or mutant TOR2-mTOR were serially diluted by 1
plasmids were used as a negative and positive control, respectively.
(E) Summary of gatekeeper mutations and their effects on mTOR kinase function.normal mTOR function (Figure 7D). Notably, I2237 can only
tolerate hydrophobic substitutions, underscoring the importance
of this hydrophobic environment.
To verify our yeast-based results, several loss-of-function
mTOR mutants (Figure 7E) were expressed as Flag-tagged pro-
teins in HEK293T cells and assayed for kinase activity in vitro us-
ing recombinant 4E-BP1 as a substrate (Figure 7F). Severe loss
of kinase activity was confirmed, validating the yeast results. Hy-
drophobic interactions are known to be important for binding of
ATP and TKIs in the ATP-binding pockets of protein tyrosine
kinases (Zhang et al., 2009). Our results demonstrate that the
hydrophobic environment of the ATP-binding pocket is also crit-
ical for catalytic function of mTOR, an atypical protein serine/
threonine kinase.
DISCUSSION
Small-molecule kinase inhibitors are proven clinically effective
against malignancies in which kinase targets are hyper-acti-
vated, driving uncontrolled growth and proliferation. However,
tumors typically develop drug resistance within 6 months after
initial treatment. A major mechanism underpinning acquired
resistance to kinase inhibitors is binding-site mutations (Gorre
et al., 2001; Heinrich et al., 2003; Kobayashi et al., 2005). Thus,
identification of resistant mutations is crucial for clinical diag-
nosis and development of new strategies to overcome resistant
variants. To this end, we have developed a robust yeast tool to
screen and study drug-resistant mutations in mTOR kinase
domain. By simply measuring yeast growth, it enables the iden-
tification and analysis of residues inmTOR kinase domain crucial
for mTOR functions and drug resistance.
Unlike mammalian cells, yeast cells are poorly permeable to
small molecules due to the unique cell wall and plasma mem-
brane structures, which have been amajor barrier for using yeast
for drug research and screens (Emter et al., 2002; Simon and
Bedalov, 2004). Yeast strains with deletion of ERG6 (alteration
in membrane composition by inhibiting ergosterol biosynthesis),
PDR1, and PDR3 (decrease in drug efflux) have been developed
to improve drug permeability (Dunstan et al., 2002). However, the
major drawback of erg6D strain is dramatically decreased
plasmid transformation efficiency and sexual conjugation, which
limit yeast as a useful tool for drug screening (Gaber et al., 1989).
Here, we found that the antifungal drug amphotericin B can
enhance cell permeability to structurally diversemTOR kinase in-
hibitors. Curiously, miconazole, a potent inhibitor of ergosterol
biosynthesis, fails to enhance drug sensitivity, suggesting that
targeting this lipid pathway alone is an ineffective strategy.
Therefore, amphotericin B may be broadly useful for different
classes of small molecules, significantly expanding yeast as a
general tool for drug discovery.
Gatekeeper residues are common locations for acquisition of
TKI drug resistance. Unlike most protein kinases that have a-fold and assayed for drug sensitivity on SC-leucine plates containing BEZ235,
e presence of amphotericin B.
0-fold and assayed for cell growth at different temperatures. Vector and TOR2
+, normal function; -, minor defect; –, moderate defect; and —, severe defect.
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Figure 4. Identification of a Hot Spot for Drug-Resistant Mutations in mTOR Kinase Domain
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bulky gatekeeper residue (e.g., methionine), more than 40% of
tyrosine kinases utilize a threonine at this position. The presence
of a small gatekeeper residue in the tyrosine kinases appears to
make them more amenable to regulation. In PI3Ks and PI3K-
related kinases, the gatekeeper is a bulky isoleucine residue
(except for leucine in ATM). The presumptive mTOR gatekeeper
residue, I2237, is located in the N-lobe hydrophobic pocket,
where it is thought to engage in hydrophobic interaction with
the adenine moiety of ATP. Strikingly, only substitution with
leucine, methionine, or valine is tolerated at this position. Any
other substitution causes a severe loss in mTOR kinase function.
A similar phenomenon was observed with the isoleucine gate-
keeper residue (I848) in p110-PI3Ka (Vogt, 2008; Zunder et al.,
2008). Thus, the relatively bulky gatekeeper residue and the
importance of gatekeeper residue in maintaining the hydropho-
bic pocket almost certainly limit its contribution to drug resis-
tance in mTOR and PI3Ka.
The drug-resistant mutation hot spot L2185 is also part of
N-lobe hydrophobic pocket. Because L2185 is further away
from ATP than I2237, it appears more tolerant to substitution
by smaller hydrophobic residues (e.g., alanine and cysteine),
while creating an incipient cavity in the active site that destabi-
lizes binding of mTOR inhibitors (e.g., AZD8055, INK128, OSI-
027, and PP242) via loss of van der Waals contact(s) (Figures
S4A and S4B). Therefore, unlike gatekeeper mutations in tyro-
sine kinases, where substitution of the smaller residue to a
bulkier side chain constrains drug binding (Taylor and Kornev,
2011), mutation of L2185 of mTOR to a smaller residue such as
alanine results in drug resistance by weakening drug binding.
It is remarkable that mutation of L2185 does not confer resis-
tance to either Torin2 or BEZ235, both of which have three-ring
fused heterocyclic structure. The distance between L2185 and
the adenine-like tricyclic ring of Torin2 (3.9 A˚) is farther away
than PP242 (3.4 A˚; Figure S4C). Because hydrophobic interac-
tion strength decreases rapidly with increasing separation,
L2185 would appear to play a less-significant role in stabilizing
binding of Torin2 versus PP242. Thus, substitution of leucine
with an alanine has less impact on Torin2 binding (as opposed
to PP242). The tricyclic Torin2 ring is thought to stack with
W2239 of mTOR and stabilize the drug binding (Yang et al.,
2013). Such a stacking interaction may, therefore, mitigate any
decrease in productive hydrophobic interactions caused by
L2185 mutations and maintain the sensitivity of either Torin2 or
BEZ235. This observation suggests that incorporation of chemo-
types isostructural to the tricyclic ring of Torin2 would be advan-
tageous in minimizing acquired drug resistance. Knowledge of
gatekeepermutations has aided discovery of second-generation
TKIs, such as bafetinib and dasatinib, which appear less suscep-
tible to drug-resistant mutations (Santos et al., 2010; Tokarski
et al., 2006). Moreover, such inhibitors should be reserved for
only L2185 mutant tumors. Our characterization of L2185 muta-(B) tor2-dg cells expressing WT or mutant TOR2-mTOR were serially diluted by
presence of amphotericin B. Vector and TOR2 were used as controls. Drug-resis
OSI-027).
(C) Systematic mutational analysis of L2185 on drug resistance. tor2-dg cells ex
were serially diluted by 10-fold and tested for sensitivity to different mTOR kinase i
supplemented with amphotericin B.tions may be useful in improving the design of mTOR kinase in-
hibitors and treatment strategy.
In addition to identifying drug-resistant mutations, our yeast
system is useful for probing the structure and function of
mTOR kinase domain. In a typical protein kinase catalytic
domain, there are two hydrophobic pockets inside the active
site critical for adenine binding (Liu and Gray, 2006). We found
that a cluster of conserved hydrophobic residues in the N-lobe
is critical for maintaining mTOR kinase function. In a previous
study of protein kinase A (PKA) also in a S. cerevisiae system,
most residues within the ATP-binding pocket of PKA were
tolerant to mutations (Kennedy et al., 2009). In contrast, the
data herein show that mutation of conserved hydrophobic resi-
dues in mTOR active site is not well tolerated and caused sub-
stantial loss of catalytic function (Figure 7C). These distinctions
likely reflect evolutionary differences in kinase regulation be-
tween atypical protein kinases (e.g., mTOR) and the canonical
protein kinases (e.g., PKA).
Conserved residues of the hydrophobic core of the PKA cata-
lytic domain have been extensively characterized by Taylor and
co-workers (Kornev et al., 2006; Meharena et al., 2013; Taylor
and Kornev, 2011). 3D alignment of the structures of PKA (PDB
ID code 1ATP) and mTOR (4JSP) permitted presumptive identi-
fication of mTOR residues corresponding to the R- and C-spines
of PKA (Figures S4D and S4E). Our structural alignment docu-
ments that mTOR residues I2163 and L2185 (both characterized
herein) correspond to PKA C-spine residues V57 and A70,
respectively (Figures S4D and S4E). We suggest, therefore,
that mutation of either I2163 or L2185 impairs mTOR catalytic
activity by disrupting the structure of the C-spine of this atypical
protein kinase. In PKA, three ‘‘shell’’ residues (V104 [Sh1], M120
[Sh2], andM118 [Sh3]) stabilize the structure of the R-spine (Me-
harena et al., 2013). Within mTOR, these three residues corre-
spond to Y2225 (Sh1), I2237 (Sh2), and G2235 (Sh3). Lack of
conservation of these shells resides between PKA and mTOR
suggests that the R-spine of mTOR may not be as dynamic as
its counterpart in PKA. The latter might fill the adenine pocket
and prevent binding of ATP. It is also interesting to note that,
similar to RAF kinase, the equivalents of I2163 and L2185 can
tolerate smaller hydrophobic residues, but not phenylalanine
(Hu et al., 2011, 2013; Shaw et al., 2014). Phenylalanine might
fill the adenine pocket and prevent binding of ATP. Finally, the
salt bridge between the C- and R-spines (E91[OE2]-K72[NZ] =
3.6 A˚) in PKA corresponds to an analogous salt bridge in
mTOR (E2190[OE1]-K2187[NZ] = 2.8A˚; Figure S4F), which could
control the catalytic activity as well as bridge the two spines as
seen with PKA (Taylor and Kornev, 2011). Whereas the impor-
tance of hydrophobic environment and hydrophobic structures
are well studied in the canonical protein kinases, it is much
less well understood in the atypical kinase such as mTOR. It
would be of considerable interest to elucidate the function of10-fold and assayed for sensitivity to different mTOR kinase inhibitors in the
tant assay was performed at 37C in the presence of amphotericin B (except
pressing WT or mutant TOR2-mTOR carrying all possible mutations at L2185
nhibitors at 37C. AZD8055, BEZ235, INK128, PF-04691502, and PKI-587were
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Figure 5. L2185A Mutation Confers Resistance to mTOR Kinase Inhibitors in Colorectal Cancer Models
(A) SW480 cells carrying homozygous WT mTOR or L2185A mutant alleles were treated with various concentrations of AZD8055, INK-128, OSI-027, and PP242
for 2 days. Growth of SW480 cells was measured by SRB assay. Data represent means ± SD in three independent experiments.
(legend continued on next page)
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hydrophobic residues in mTOR, which could help improve future
design of mTOR kinase inhibitors.
Unlike cancer-driving mutations, drug-resistant mutations are
not readily detectable until clinical resistance is developed.
Because mTOR kinase inhibitors have not yet been approved
for human use, the clinical significance of the non-gatekeeper
hot spot mutations remains to be determined. Nonetheless,
our findings can impact the field in several ways. First, the
drug-resistant mutation profiles could provide guidance for
monitoring the potential occurrence of drug-resistant mutations
during human clinical trials. Second, our study provides valuable
insights into the structure-function relationship of mTOR kinase.
It provides insights into the mechanism of action for mTOR ki-
nase inhibitors and drug resistance, which can help with design
of future mTOR inhibitors. Finally, drug-resistant mTOR mutants
can be powerful tools for probing the physiological functions
of mTOR kinase, as does the rapamycin-resistant mTOR mu-
tants that have made many contributions to understanding of
mTORC1.
EXPERIMENTAL PROCEDURES
Plasmids, Mutagenesis, and Library Screen
The TOR2-mTOR hybrid plasmid was constructed by replacing the C-terminal
region of TOR2 of pML40-TOR2 (Alarcon et al., 1996; encoding for 2,080–
2,474 aa) in frame with a DNA fragment corresponding to C-terminal domain
of mTOR (encoding for 2,140–2,549 aa). To construct mutant TOR2-mTOR
plasmids,mTOR C-terminal region was amplified by PCR and co-transformed
into yeast with XmaI-digested pML40-TOR2 plasmid that excised the TOR2
C-terminal region. The resultant TOR2-mTOR fusion plasmids are constructed
in reading frame by gap repair in yeast.
The WT and kinase-dead pCDNA3-Flag-mTOR plasmids were obtained
from Addgene. The I2163K, L2185A, L2185C, L2185P, and I2237S mutant
plasmids were constructed by using overlap extension-PCR method for
site-directed mutagenesis. For site-specific saturation mutagenesis, pUC18-
mTOR kinase plasmid was constructed by insertion of mTOR C-terminal
domain (aa 2,140–2,549) into pUC18 vector at the XmaI site. The pUC18-
mTOR plasmid was mutagenized at the I2163, L2185, Y2225, I2237, and
W2239 residues by degenerate PCR with NNK primers. The mutation library
was constructed using QuikChange mutagenesis kit according to the manu-
facturer’s instruction (Agilent) and transformed into chemically competent
E. coli. Plasmid DNA was extracted by miniprep kit (Promega), and the muta-
tions were verified by sequencing.
Yeast Strains and Culture and Growth Assays
The tor2-dg temperature-sensitive strain was generated from the W303 back-
ground (MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15) as
described previously (Dohmen and Varshavsky, 2005). For the halo assay,
log-phase W303 WT or tor2-dg cells were spread evenly on YPD agarose
plates. After drying, small sterile filter discs were placed on the surface and
5 ml of rapamycin (1 mM), BEZ235 (5 mM), PKI-587 (3 mM), othermTOR inhibitors
(10 mM), or DMSO were applied to each disc. Plates were incubated at 30C
(WT) or 37C (tor2-dg) for 3 days.
To enhance yeast cell permeability, log-phase W303 tor2-dg cells were
spread evenly on SD-Leu agarose plates. After drying, small sterile filter discs(B) SW480 cells carrying homozygous WT and L2185A mutant mTOR allele were
(6,000 nM), and PP242 (2,000 nM) for different times. Cell growth was measured
means ± SD in three independent experiments.
(C) SW480 cells carrying homozygous WT and L2185A mutant mTOR were treat
1 hr. The effect on the level of P-S6K, S6K, P-4E-BP1, 4EB-P1, P-AKT, and AKT
(D) SW480 cells carrying homozygous WT and L2185A mutant mTOR alleles we
2 days. The growth of SW480 cells was measured by SRB assay. Data represenwere placed on the surface and 5 ml of indicated mTOR inhibitors or DMSO
were applied to each disc with or without adding 5 ml of amphotericin B
(10 mM), miconazole (50 mM), or caspofungin (50 mM). Plates were incubated
at 37C for 3 days. Drug-resistance profiles of TOR2-mTOR mutant cells
were determined by the spotting assay. For this assay, 10-fold serial dilutions
of cells were spotted on SD-Leu plates in the presence of indicated mTOR
inhibitors with or without amphotericin B (200 nM) and incubated at 37C for
3 days.
Cancer Cell Lines and CRISPR/Cas9-Mediated Mutagenesis
Cancer cell lines were maintained in DMEM or RPMI 1640, supplemented with
10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitro-
gen). CRISPR/cas9 technology was used to engineer mutant mTOR allele
in SW480 colorectal and H460 lung cancer cells. Briefly, the target sequence
for mTOR, GCTGCATCACACGCTCATCC, was designed through the online
tool at http://crispr.mit.edu and cloned into pSPCas9(BB)-2A-GFP vector
(PX458 in Addgene). Genomic mTOR mutation was engineered using a proto-
col as described (Ran et al., 2013) and was confirmed by targeted sequencing.
Immunological and Chemical Reagents and Proliferation Assays
Antibodies against tubulin, S6K, phospho-S6K (Thr389), 4E-BP1, phospho-
4E-BP1 (Thr37/46), AKT, phospho-AKT (Thr308), and phospho-AKT (Ser473)
were purchased from Cell Signaling Technology. For mTOR inhibitors, PI-
103, PP242, WYE-354, and WYE-132 were purchased from Chemdea;
BEZ235 was purchased from LC Laboratories; and XL765, PKI-587, PF-
04691504, OSI-027, AZD8055, INK-128, and Torin2were purchased fromSell-
eck Chemicals. For drug-sensitivity test, cancer cells were seeded in 96-well
plates at a density of 2,000 cells per well. Twenty-four hours later, different
concentrations of mTOR inhibitors were added in quadruplicate. Cell growth
was measured by the sulforhodamine B (SRB) assay as previously described
(Vichai and Kirtikara, 2006).
In Vitro mTOR Kinase Assay
The mTOR kinase activity was assessed by in vitro kinase assay as described
(Sancak et al., 2007). Briefly, pCDNA3-Flag-mTOR variants were transfected
into HEK293T cells by calcium phosphate transfection. After 48 hr, cells
were washed with ice-cold PBS buffer and lysed with lysis buffer (40 mM
HEPES [pH 7.4], 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophos-
phate, 0.3% CHAPS, protease inhibitor cocktail [Roche], phosSTOP [Roche],
and 1 mM PMSF [Sigma]). Cell lysates were incubated with anti-Flag M2 anti-
body (Sigma) for 1.5 hr, which was followed by 1 hr incubation with Protein A/G
PLUS-Agarose (Santa Cruz). The immunoprecipitates were washed twice with
washing buffer (40 mM HEPES [pH 7.4], 150 mM NaCl, 2 mM EDTA, 10 mM
pyrophosphate, 10 mM glycerophosphate, and 0.3%CHAPS) and three times
with IP buffer (25 mM HEPES [pH 7.4] and 20 mM KCl). Kinase assay was per-
formed in 15 ml kinase buffer (25 mM HEPES [pH 7.4], 50 mM KCl, 10 mM
MgCl2, and 250 mM ATP) containing 150 ng of GST-4E-BP1 for 20 min at
30C. The kinase reaction was stopped by adding 30 ml 2-fold SDS sample
buffer and incubated at 95C for 5 min. Phosphorylation of 4E-BP1 was
analyzed by western blot.
Xenograft Tumor Models
Female athymic NCr-nu/nu mice (4–6 weeks old) were obtained from Taconic
Farms. They were injected subcutaneously into the left flank with 2 3 106
SW480 WT or mutant cells to establish xenograft tumors. Three days after
injection, mice were randomly divided into three groups (eight animals per
group). Group 1 was given 1 mg/kg INK128, group 2 was given 0.3 mg/kg
INK128, and group 3 was given the vehicle used for administration (vehicletreated with a single dose of AZD8055 (100 nM), INK-128 (100 nM), OSI-027
by SRB assay. The drug carrier DMSO was used as a control. Data represent
ed with various concentrations of INK-128, OSI-027, AZD8055, and PP242 for
was analyzed by immunoblot.
re treated with various concentrations of BEZ235, PF-0691502, and Torin2 for
t means ± SD in three independent experiments.
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Figure 6. L2185A Mutation Renders Resistance of Xenograft Tumors to mTOR Kinase Inhibitors
(A) Mice bearing xenograft tumors derived from SW480 cells expressing WT mTOR were administered with INK128 at 1 mg/kg or 0.3 mg/kg, once daily via
intraperitoneal injection. Shown are representative animals and excised tumors after drug treatment.
(B) Same as (A) except xenograft tumors were derived from SW480 carrying homozygous mTOR(L2185A) alleles.
(C) Tumor volume measurement for SW480 xenograft tumors expressing mTOR (WT; expressed as means ± SD; n = 8; *p < 0.01; versus vehicle control).
(D) Tumor volume measurement for SW480 xenograft tumors expressing mTOR(L2185A) mutant (expressed as means ± SD; n = 8).
(E) Tissue extracts from xenograft tumors at the end of treatment with or without 1 mg/kg INK128 were analyzed for the level of P-S6K, S6K, P-S6, S6, P-4E-BP1,
4E-BP1, P-AKT, and AKT by immunoblot. Six tumor samples from each animal group were shown with each lane representing an individual tumor sample.control [VC]). INK128 was used according to previous studies, which were at
much lower doses than the reported maximum tolerated doses (Gild et al.,
2013; Hayman et al., 2014; Hsieh et al., 2012). INK128 was administered
once daily via intraperitoneal injection (i.p.) with freshly prepared drug solution
in 100 ml of PBS (final DMSO concentration = 0.33%) just before administra-
tion. Bidimensional tumor measurements were taken every 2 days, and mice456 Cell Reports 11, 446–459, April 21, 2015 ª2015 The Authorswere weighed once weekly. Tumor volumewas calculated by the following for-
mula: tumor volume (mm3) = (shorter diameter2 3 longer diameter)/2 and are
presented as means ± SD (n = 8; Zhang and Zheng, 2012). For analysis of
signaling inhibition, tumor tissues were removed from the animals after admin-
istration of the last dose of drug and immediately frozen in liquid nitrogen. Tis-
sue extracts were prepared for analysis of mTOR signaling by western blot.
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Figure 7. Saturation Mutagenesis of Highly Conserved Hydrophobic Residues of mTOR Kinase Domain
(A) Shown is hydrophobic surface representation of the ATP-binding pocket of mTOR kinase bound with an ATP molecule (PDB ID code 4JSP). ATP atoms are
colored as follows: Mg+2, green; N, blue; O, red; P, orange; S, yellow. Protein surface representation is as follows: hydrophilic residue, blue; hydrophobic residue,
red; neutral residue, white.
(B) Summary of the effect of mutations at different conserved hydrophobic residues in mTOR kinase domain.
(legend continued on next page)
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The animal studies were approved by Rutgers University Institutional Animal
Care and Use Committee and carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals
of the NIH.
Modeling of L2185A mTOR Kinase Domain
An atomic model of the L2185A mutant form of the mTOR kinase domain was
generated via deletion of the Cg, Cd1, and Cd2 atoms of residue 2,185. Intra-
tomic distances between the Cb atom of the modeled mutant enzyme and
PP242, Torin, and ATP were estimated directly by assuming that the position
of the bound ligand was unaffected by the mutation.
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